Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Transplantation

Pre-emptive CMV therapy versus universal CMV prophylaxis in renal transplant recipients

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

  1. Reischig, T. et al. Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. J. Am. Soc. Nephrol. doi:10.1681/ASN.2012010100

Download references

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kelsey, R. Pre-emptive CMV therapy versus universal CMV prophylaxis in renal transplant recipients. Nat Rev Nephrol 8, 614 (2012). https://doi.org/10.1038/nrneph.2012.210

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrneph.2012.210

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing